BT
ALXN

Beacon Trust’s Alexion Pharmaceuticals ALXN Stock Holding History

Beacon Trust’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$238K Sell
1,814
-54
-3% -$6.96K 0.04% 165
2016
Q4 		$229K Sell
1,868
-100
-5% -$12.2K 0.04% 168
2016
Q3 		$241K Sell
1,968
-1,071
-35% -$138K 0.04% 159
2016
Q2 		$355K Sell
3,039
-18,747
-86% -$2.66M 0.06% 146
2016
Q1 		$3.03M Sell
21,786
-7,105
-25% -$1.04M 0.53% 64
2015
Q4 		$5.51M Buy
28,891
+317
+1% +$55.4K 0.96% 37
2015
Q3 		$4.47M Sell
28,574
-5,516
-16% -$1.01M 0.79% 45
2015
Q2 		$6.16M Sell
34,090
-1,464
-4% -$253K 0.99% 34
2015
Q1 		$6.16M Sell
35,554
-123
-0.3% -$22.3K 0.94% 36
2014
Q4 		$6.6M Buy
35,677
+21
+0.1% +$3.89K 1.02% 35
2014
Q3 		$5.91M Sell
35,656
-953
-3% -$157K 0.98% 38
2014
Q2 		$5.72M Sell
36,609
-1,999
-5% -$316K 0.94% 45
2014
Q1 		$5.87M Sell
38,608
-4,563
-11% -$726K 1% 39
2013
Q4 		$5.74M Buy
43,171
+1,852
+4% +$222K 0.99% 37
2013
Q3 		$4.8M Sell
41,319
-1,104
-3% -$121K 0.89% 50
2013
Q2 		$3.91M Buy
+42,423
New +$4.09M 0.74% 53

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Beacon Trust's ALXN Position: Q1 2017 in Review

Beacon Trust reduced its Alexion Pharmaceuticals (ALXN) stake by 2.9% in Q1 2017, selling an estimated $6.96K and leaving 1,814 shares worth $238K. The position accounts for 0.04% of the portfolio, ranked #165.

Beacon Trust first reported a position in ALXN in Q2 2013 and has held it in 16 quarters since. The position peaked at $6.6M in Q4 2014. 561 funds tracked by Wall St. Rank hold ALXN as of Q1 2017.

  • Beacon Trust held 1,814 shares of Alexion Pharmaceuticals worth $238K as of Q1 2017.
  • Beacon Trust sold 54 Alexion Pharmaceuticals shares in Q1 2017, an estimated $6.96K.
  • Alexion Pharmaceuticals made up 0.04% of Beacon Trust's portfolio in Q1 2017, its #165 holding.
  • Beacon Trust first reported a position in Alexion Pharmaceuticals in Q2 2013 and has held it in 16 quarters since.
  • Beacon Trust's Alexion Pharmaceuticals position peaked at $6.6M in Q4 2014.
  • 561 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2017.

Based on Beacon Trust's 13F filing for Q1 2017, filed 9 May 2017.